Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial.
Journal
The Lancet. Rheumatology
ISSN: 2665-9913
Titre abrégé: Lancet Rheumatol
Pays: England
ID NLM: 101765308
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
pubmed:
6
10
2020
medline:
6
10
2020
entrez:
5
10
2020
Statut:
ppublish
Résumé
Severe COVID-19 is characterised by inflammation and coagulation in the presence of complement system activation. We aimed to explore the potential benefit and safety of selectively blocking the anaphylatoxin and complement protein C5a with the monoclonal antibody IFX-1 (vilobelimab), in patients with severe COVID-19. We did an exploratory, open-label, randomised phase 2 trial (part of the adaptive phase 2/3 PANAMO trial) of intravenous IFX-1 in adults with severe COVID-19 at three academic hospitals in the Netherlands. Eligibility criteria were age 18 years or older; severe pneumonia with pulmonary infiltrates consistent with pneumonia, a clinical history of severe shortness of breath within the past 14 days, or a need for non-invasive or invasive ventilation; severe disease defined as a ratio of partial pressure of arterial oxygen to fractional concentration of oxygen in inspired air (PaO Between March 31 and April 24, 2020, 30 patients were enrolled and randomly assigned to the IFX-1 group (n=15) or the control group (n=15). During the study it became clear that several patients could not be assessed regularly in the supine position because of severe hypoxaemia. It was therefore decided to focus on all PaO In this small exploratory phase 2 part of the PANAMO trial, C5a inhibition with IFX-1 appears to be safe in patients with severe COVID-19. The secondary outcome results in favour of IFX-1 are preliminary because the study was not powered on these endpoints, but they support the investigation of C5a inhibition with IFX-1 in a phase 3 trial using 28-day mortality as the primary endpoint. InflaRx.
Sections du résumé
BACKGROUND
BACKGROUND
Severe COVID-19 is characterised by inflammation and coagulation in the presence of complement system activation. We aimed to explore the potential benefit and safety of selectively blocking the anaphylatoxin and complement protein C5a with the monoclonal antibody IFX-1 (vilobelimab), in patients with severe COVID-19.
METHODS
METHODS
We did an exploratory, open-label, randomised phase 2 trial (part of the adaptive phase 2/3 PANAMO trial) of intravenous IFX-1 in adults with severe COVID-19 at three academic hospitals in the Netherlands. Eligibility criteria were age 18 years or older; severe pneumonia with pulmonary infiltrates consistent with pneumonia, a clinical history of severe shortness of breath within the past 14 days, or a need for non-invasive or invasive ventilation; severe disease defined as a ratio of partial pressure of arterial oxygen to fractional concentration of oxygen in inspired air (PaO
FINDINGS
RESULTS
Between March 31 and April 24, 2020, 30 patients were enrolled and randomly assigned to the IFX-1 group (n=15) or the control group (n=15). During the study it became clear that several patients could not be assessed regularly in the supine position because of severe hypoxaemia. It was therefore decided to focus on all PaO
INTERPRETATION
CONCLUSIONS
In this small exploratory phase 2 part of the PANAMO trial, C5a inhibition with IFX-1 appears to be safe in patients with severe COVID-19. The secondary outcome results in favour of IFX-1 are preliminary because the study was not powered on these endpoints, but they support the investigation of C5a inhibition with IFX-1 in a phase 3 trial using 28-day mortality as the primary endpoint.
FUNDING
BACKGROUND
InflaRx.
Identifiants
pubmed: 33015643
doi: 10.1016/S2665-9913(20)30341-6
pii: S2665-9913(20)30341-6
pmc: PMC7521913
doi:
Banques de données
ClinicalTrials.gov
['NCT04333420']
Types de publication
Journal Article
Langues
eng
Pagination
e764-e773Informations de copyright
© 2020 Elsevier Ltd. All rights reserved.
Références
Clin Immunol. 2017 Jul;180:25-32
pubmed: 28366510
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Nat Rev Immunol. 2020 Jun;20(6):343-344
pubmed: 32327719
Intensive Care Med. 2020 Jun;46(6):1089-1098
pubmed: 32367170
Transl Res. 2020 Jun;220:1-13
pubmed: 32299776
Blood. 2009 Aug 20;114(8):1675-83
pubmed: 19535796
Nat Rev Immunol. 2020 Jun;20(6):363-374
pubmed: 32346093
Front Immunol. 2019 Jun 14;10:1348
pubmed: 31258531
J Allergy Clin Immunol. 2020 Jul;146(1):215-217
pubmed: 32417135
Clin Infect Dis. 2015 Feb 15;60(4):586-95
pubmed: 25433014
Emerg Microbes Infect. 2018 Apr 24;7(1):77
pubmed: 29691378
Clin Immunol. 2020 Jun;215:108450
pubmed: 32360516
Lancet. 2020 May 9;395(10235):1517-1520
pubmed: 32311318
Kidney Int. 2020 Aug;98(2):314-322
pubmed: 32461141
Emerg Microbes Infect. 2015 May;4(5):e28
pubmed: 26060601
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
N Engl J Med. 2020 Jul 9;383(2):120-128
pubmed: 32437596
Nature. 2020 Jul 29;:
pubmed: 32726800
J Immunol. 2008 Jun 1;180(11):7368-75
pubmed: 18490736
Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):438-41
pubmed: 15692257
Thromb Haemost. 1997 Feb;77(2):394-8
pubmed: 9157602
J Immunol. 2006 Oct 1;177(7):4794-802
pubmed: 16982920
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Circulation. 2020 Jun 2;141(22):1739-1741
pubmed: 32271624